Literature DB >> 16768459

Characterization of the secondary structure and stability of an RNA aptamer that binds vascular endothelial growth factor.

Melanie Bozza1, Richard D Sheardy, Enrique Dilone, Stephen Scypinski, Margaret Galazka.   

Abstract

Thermal denaturation studies and spectroscopic studies were employed to investigate the secondary structure and stability of an RNA-PEG conjugate commercially called Macugen. The RNA aptamer is conjugated to a pegylated moiety, and the majority of its 2'-hydroxyl groups are methylated or otherwise modified. UV optical melting studies and differential scanning calorimetry (DSC) were carried out under different conditions to evaluate the effects of Na+ and oligomer concentrations on the stability of the secondary structure of the RNA oligomer. The results of these studies indicated that the T(m) of the RNA is independent of oligomer concentration but dependent on the salt concentration, in a predictable fashion. Further, the DSC melting profiles obtained under all conditions were highly reversible. Circular dichroism (CD) studies were determined under different salt concentrations, various RNA concentrations, and temperatures as well. Together, the thermal denaturation and CD studies provide evidence that the secondary structure of the RNA oligonucleotide is a stable hairpin at 25 degrees C and that the thermally induced hairpin to single strand transition is highly reversible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16768459     DOI: 10.1021/bi0521442

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  3 in total

1.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors.

Authors:  Justin P Dassie; Xiu-Ying Liu; Gregory S Thomas; Ryan M Whitaker; Kristina W Thiel; Katie R Stockdale; David K Meyerholz; Anton P McCaffrey; James O McNamara; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2009-08-23       Impact factor: 54.908

Review 2.  Current progress on aptamer-targeted oligonucleotide therapeutics.

Authors:  Justin P Dassie; Paloma H Giangrande
Journal:  Ther Deliv       Date:  2013-12

3.  Architecture of high-affinity unnatural-base DNA aptamers toward pharmaceutical applications.

Authors:  Ken-ichiro Matsunaga; Michiko Kimoto; Charlotte Hanson; Michael Sanford; Howard A Young; Ichiro Hirao
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.